TG Therapeutics, Inc. (TGTX) News
Follow TG Therapeutics, Inc. (TGTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 24 public stories across 14 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Novartis Reports Weaker-Than-Expected Remibrutinib Relapse Data
Conference data showed remibrutinib meaningfully reduced multiple-sclerosis relapses, but less than analysts had expected.
EQUITY | Oct 23, 2026, 05:49 PM UTC
L
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm
NEW YORK, Sept. 28, 2026 // -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TG Therapeutics, Inc. (NASDAQ:TGTX) breached their fiduciary duties to shareho
NEWS | Sep 28, 2026, 01:09 PM UTC
H
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach
The biotech sector is heading into the third-quarter earnings season with a tug-of-war between higher interest rates and an unusually heavy pipeline of company-specific catalysts. The SPDR S&P Biotech ETF (NYSE: XBI ) is
LIVE | Sep 25, 2026, 08:19 PM UTC
L
TG Therapeutics CEO to participate in H.C. Wainwright 28th conference
TG Therapeutics said Michael S. Weiss, Chairman and CEO, will join a fireside chat scheduled for Monday, September 14, 2026 at 12:00pm ET.
EQUITY | Sep 10, 2026, 11:32 AM UTC
L
TG Therapeutics to participate in H.C. Wainwright conference
MACRO | Sep 10, 2026, 11:30 AM UTC
M
TGTX BRIUMVI on track for $1B run rate amid pipeline expansion
BRIUMVI is on track for a $1 billion run rate, supported by commercial expansion and a clinical pipeline targeting MS and other indications. SubQ formulation is expected to drive future growth, with patent protection ext
CENTRAL_BANK | Sep 09, 2026, 05:03 PM UTC
L
TGTX says BRIUMVI targets $1B+ run rate amid dosing changes
TGTX says BRIUMVI is on track for a $1 billion run rate, citing expanded marketing and simplified dosing plus subQ formulations. The company also expects higher peak sales than current estimates, backed by patent protect
EARNINGS | Sep 09, 2026, 04:35 PM UTC
L
TG Therapeutics CEO to participate in Cantor Global Healthcare conference
Michael S. Weiss, TG Therapeutics chairman and CEO, will take part in a fireside chat on Wednesday, September 9, 2026, at 11:30am ET.
EQUITY | Sep 03, 2026, 11:39 AM UTC
L
TGTX - TG Therapeutics to Participate in the Cantor Global Healthcare Conference
TGTX - TG Therapeutics to Participate in the Cantor Global Healthcare Conference
EQUITY | Sep 03, 2026, 11:30 AM UTC
M
TGTX opens lower but pares losses on Novartis data, Wainwright note
TG Therapeutics (TGTX) opened lower Tuesday, then pared losses as investors digested Novartis multiple sclerosis pill data and an H.C. Wainwright note from Emily Bodnar saying the results do not threaten Briumvi.
EQUITY | Sep 01, 2026, 07:28 PM UTC
L
HC Wainwright & Co. maintains TG Therapeutics $78 price target
HC Wainwright & Co. maintained its $78.00-per-share price target for TG Therapeutics, according to Benzinga ratings actions.
EQUITY | Sep 01, 2026, 05:20 PM UTC
L
TG Therapeutics Posts Q2 EPS $0.05
TG Therapeutics reports Q2 earnings
EARNINGS | Aug 03, 2026, 11:05 AM UTC
L
TGTX Q2 EPS $0.05 Misses Estimates
TGTX misses Q2 EPS estimates
EARNINGS | Aug 03, 2026, 11:03 AM UTC
L
TG Therapeutics Raises FY2026 Sales Guidance from $925.000M to $950.000M vs $942.370M Est
TG Therapeutics (NASDAQ: TGTX ) raises FY2026 sales outlook from $925.000 million to $950.000 million vs $942.370 million estimate.
EARNINGS | Aug 03, 2026, 11:00 AM UTC
L
TGTX - TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance
TGTX - TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance
EARNINGS | Aug 03, 2026, 11:00 AM UTC
L
TGTX Tg Therapeutics RESULTS: Q2, Q2 Operating Income $21.674M, Q2 Net Income $7.781M, Q2 product REV $235.794M
TGTX Tg Therapeutics RESULTS: Q2, Q2 Operating Income $21.674M, Q2 Net Income $7.781M, Q2 product REV $235.794M
EARNINGS | Aug 03, 2026, 11:00 AM UTC
H
Implied EPS movers for Monday AM: MAR +/-0.9%, KRYS +/-11.5%, TSN +/-6.6%, TGTX +/-12.0%, TWST +/-18.9%, L +/-4.3%, HESM +/-5.2%, CNH +/-8.0
Implied EPS movers for Monday AM: MAR +/-0.9%, KRYS +/-11.5%, TSN +/-6.6%, TGTX +/-12.0%, TWST +/-18.9%, L +/-4.3%, HESM +/-5.2%, CNH +/-8.0%, MMYT +/-11.7%, CNA +/-5.7%, SRAD +/-13.5%, AVA +/-6.4%, ABTC +/-14.7%, SBH +/
EARNINGS | Jul 31, 2026, 06:05 PM UTC
L
TGTX - TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update
TGTX - TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update
EARNINGS | Jul 29, 2026, 11:30 AM UTC
L
TGTX Raise PT to $86 from $55 and remain Buyers into the early-August Q2 print - believes the ~$220M US BRIUMVI guide looks like a floor, wi
TGTX Raise PT to $86 from $55 and remain Buyers into the early-August Q2 print - believes the ~$220M US BRIUMVI guide looks like a floor, with modest beat more likely than not @ Briley
EQUITY | Jul 27, 2026, 01:04 PM UTC
L
TGTX PT raised to $86 at B.Riley
TGTX PT raised to $86 at B.Riley
EQUITY | Jul 27, 2026, 11:59 AM UTC
H
Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says
() -- Moderna (MRNA), TG Therapeutics (TGTX), and Agios Pharmaceuticals (AGIO) will see increased scrutiny during their upcoming Q2 results on ongoing drug launches after their outperformance year to date, BofA Securitie
EARNINGS | Jul 07, 2026, 03:04 PM UTC
H
TG Therapeutics price target raised to $20 from $17 at BofA
BofA analyst Alec Stranahan raised the firm's price target on TG Therapeutics to $20 from $17 and keeps an Underperform rating on the shares. TG Therapeutics' Q2 print will likely center on whether Briumvi continues to e
EARNINGS | Jul 07, 2026, 01:18 PM UTC
L
TG Therapeutics Starts Phase 2 Clinical Study Of BRIUMVI In Adult Participants With Treatment-Resistant Schizophrenia
TG Therapeutics, Inc. (NASDAQ: TGTX ) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant schizophrenia. The Phase 2 study is an open-labe
EQUITY | Jul 06, 2026, 11:33 AM UTC
L
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at on our options activity scanner. Traders often look for
EQUITY | Jul 01, 2026, 05:35 PM UTC